Stabilized factor VIII with engineered disulfide bonds

(19)

(11)

EP 2 110 385 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 A1)

(48)	Corrigendum issued on:
	02.06.2010 Bulletin 2010/22

(43)	Date of publication:
	21.10.2009 Bulletin 2009/43

(21)	Application number: 09159506.6

(22)	Date of filing: 14.06.2002

(51)

International Patent Classification (IPC):

C07K 14/755^(2006.01)
C12N 15/12^(2006.01)

A61K 38/37^(2006.01)

(84)	Designated Contracting States:
	DE ES FR GB IT

(30)

Priority:

14.06.2001 US 298578 P

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	02737516.1 / 1421539

(71)	Applicant: The Scripps Research Institute
	La Jolla, CA 92037 (US)

(72)	Inventors:
	Griffin, John H Del Mar, CA 92014 (US) Gale, Andrew J San Diego, CA 92126 (US) Getzoff, Elizabeth D San Diego, CA 92107 (US) Pellequer, Jean-Luc 30200 Bagnols sur Cèze (FR)

(74)	Representative: Elend, Almut Susanne et al
	Venner Shipley LLP Byron House Cambridge Business Park Cowley Road Cambridge CB4 0WZ Cambridge CB4 0WZ (GB)


	Remarks:
	This application was filed on 06-05-2009 as a divisional application to the application mentioned under INID code 62.

(54)	Stabilized factor VIII with engineered disulfide bonds

(57) The present invention relates to methods of introducing one or more cysteine residues into a polypeptide which permit the stabilization of the polypeptide by formation of at least one bond, preferably a disulfide bond, between different domains of the polypeptide. The invention also relates to polypeptides containing such introduced cysteine residue(s), nucleic acids encoding such polypeptides and pharmaceutical compositions comprising such polypeptides or nucleic acids. The invention also relates to vectors, viral particles and host cells containing such nucleic acids, and methods of using them to produce the polypeptides of the invention. Exemplified polypeptides include plasma proteins, including hepatocyte growth factor activator and plasma hyaluronin binding protein, as well as blood coagulation factors, such as Factor VIII, Factor V, Factor XII and prothrombin.